Q-omics provides the consensus-scored NDUFV2P1 profile across patient tissues and cancer cell-line models. NDUFV2P1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NDUFV2P1 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, NDUFV2P1 RNA expression shows 14,692 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, BRCA, and UVM as cancer lineages where NDUFV2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFV2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFV2P1 survival associations across molecular data types. NDUFV2P1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFV2P1 RNA expression–survival associations across cancer types. High NDUFV2P1 expression shows unfavorable associations in LUAD, UVM, STAD, LGG and LAML, but favorable associations in KIRP. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for NDUFV2P1 RNA expression.
This table summarizes NDUFV2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NDUFV2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFV2P1 shows lower tumor expression in KIRP and READ and higher tumor expression in BRCA, KIRC, PRAD and CHOL. The BRCA box plot shows higher NDUFV2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.337, t-test p < 0.001).
This table shows molecular features associated with NDUFV2P1 in patient tissues and cancer cell lines. In patient samples, NDUFV2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
